Exelixis
EXEL
#1670
Rank
HK$79.48 B
Marketcap
HK$278.32
Share price
0.82%
Change (1 day)
68.60%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - P/B ratio

P/B ratio as of November 2024 : 4.49

According to Exelixis's latest financial reports the company has a price-to-book ratio of 4.91148.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.

Exelixis - P/B ratio (from 2001 to 2024)

P/B ratio by year

Year P/B ratio Change
2024-12-31N/A-100%
2023-12-313.3058.49%
2022-12-312.08-20.53%
2021-12-312.62-21.04%
2020-12-313.314.35%
2019-12-313.18-30.69%
2018-12-314.58-85.48%
2017-12-3131.6-34.79%
2016-12-3148.4-630.03%
2015-12-31-9.13271.69%
2014-12-31-2.46-114.38%
2013-12-3117.1503.03%
2012-12-312.83-60.01%
2011-12-317.08-280.23%
2010-12-31-3.93-19.11%
2009-12-31-4.86-48.44%
2008-12-31-9.42-189.13%
2007-12-3110.610.87%
2006-12-319.53-30.47%
2005-12-3113.7-2.47%
2004-12-3114.1351.72%
2003-12-313.1115.26%
2002-12-312.70

P/B ratio for similar companies or competitors

Company P/B ratio P/B ratio differencediff. Country
4.15-7.54%๐Ÿ‡ฌ๐Ÿ‡ง UK
1.67-62.72%๐Ÿ‡ซ๐Ÿ‡ท France
5.86 30.50%๐Ÿ‡บ๐Ÿ‡ธ USA
6.45 43.58%๐Ÿ‡บ๐Ÿ‡ธ USA
23.0 411.65%๐Ÿ‡บ๐Ÿ‡ธ USA
5.38 19.71%๐Ÿ‡บ๐Ÿ‡ธ USA
1.77-60.63%๐Ÿ‡บ๐Ÿ‡ธ USA
-37.7-939.84%๐Ÿ‡บ๐Ÿ‡ธ USA
18.1 302.34%๐Ÿ‡บ๐Ÿ‡ธ USA